AtaiBeckley's Final Chapter: Shareholders Trade Certainty for Milestone-Linked Upside
Published on 09/22/2026 at 14:20 | Editorial boerse-global.de
The last regulatory threads tying AtaiBeckley Inc. to the American public markets have now been cut. The company filed a Form 15 with the U.S. Securities and Exchange Commission, formally suspending its ongoing reporting obligations under the Securities Exchange Act and terminating the registration of its common stock. The move marks the closing act of a corporate life that ended when Eli Lilly and Company absorbed the biotech through its indirect subsidiary, Albali Acquisition Corporation.
That merger left AtaiBeckley standing as a wholly owned Lilly subsidiary — and left its former investors holding a two-part payout structure that splits their return between guaranteed cash and a bet on future science.
$6.75 in Cash, Plus a Conditional $2.50
Under the terms of the takeover agreement, every share of AtaiBeckley common stock converted into the right to receive $6.75 in cash, interest-free, payable according to the merger terms. On top of that, each former holder picked up a Contingent Value Right with a potential value of up to an additional $2.50 per share. Whether that second tranche ever materializes depends entirely on the transferred programs hitting specified clinical and regulatory milestones.
That is where the policy landscape becomes relevant. Reuters reported that the FDA convened a public session on September 15 addressing psychedelic therapies — part of a noticeably widening political appetite for substances such as ibogaine and psilocybin. For anyone still holding AtaiBeckley CVRs, the debate matters directly, since those compounds touch the pipeline the company carried into the Lilly fold.
Should investors sell immediately? Or is it worth buying Atai Beckley?
Options Cancelled, Insiders Converted
The merger's completion wiped out the company's outstanding equity awards. Director John Francis Hoffman saw two separate tranches extinguished: 206,000 options at an exercise price of $2.25, plus a further 121,968 options carrying a higher strike. Both were cancelled outright upon the transaction taking effect, with Hoffman receiving instead the right to a cash payment and one CVR for each underlying share.
Other insiders followed the same template. Director Amir H. Kalali disposed of his entire reported position, with his 4,666 shares converted into $6.75 per share in cash plus one CVR apiece. Press accounts indicate that Director Sabrina Martucci Johnson's options met an identical fate — annulled and exchanged for cash and contingent value rights under the same structure. The board also approved a retention bonus of $194,000 for Gerd Kochendoerfer on the closing date, net of applicable deductions and withholdings.
Nasdaq Exit Set in Motion
AtaiBeckley had already alerted the Nasdaq on September 11 that the merger was closing, requesting that trading be halted and its common stock delisted under the ticker ATAI. The company also asked the exchange to file the Form 25, which removes the shares from listing and from registration. The delisting process via Form 25 was launched alongside the Form 15 filing, and the company submitted additional post-effective amendments to fully deregister its securities under its Form S-8 plans.
For former shareholders, the arithmetic is now fixed on one side and open-ended on the other: $6.75 is settled, while the remaining $2.50 rides on whether the FDA's evolving stance on psychedelic medicine translates into the regulatory wins the CVRs require.
Ad
Atai Beckley Stock: New Analysis - 22 September
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
